Coming back to: Semaglutide in people without diabetes: what the evidence base looks like posts 31–47

The version of Semaglutide in people without diabetes that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.

Renal outcomes moved this compound out of the metabolic-only conversation. FLOW reported on kidney endpoints in people with type 2 diabetes and chronic kidney disease, which is a narrower population than the discussion here usually assumes.

The answer changed when I changed how I was measuring, which was informative.

I read post #30 twice before replying, because I had assumed the opposite.

The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.

Post #33 answers the question as asked. The question underneath it is different.

Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.

Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.

I would be glad to be shown a cleaner way of putting this.

Everything in post #33 holds. The case it does not cover is the one I have.

The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for different endpoints, so the evidence does not transfer sideways.

Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.

Worth reading the earlier posts in this thread before acting on mine.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

That has held every time I have looked, which is not the same as always.

Building on post #37 rather than restating it.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

Counter-ion form matters for the arithmetic and is almost never stated. A vial labelled 5 mg of peptide as an acetate salt and one labelled 5 mg as trifluoroacetate do not contain the same quantity of the molecule you are interested in.

Worth one more sentence than it usually gets.

Thank you — that answers what I came here to find out.

Post #41 is the version of this I will quote in future. One addition.

The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.

I would rather be precise about what I do not know than vague about what I do.

Nausea is dose-related and adaptation-related, and both are true at once. The pattern most people describe is a return of symptoms at each escalation followed by adaptation, rather than a single course of adaptation at the start.

Filing this under things that are true until someone shows me otherwise.